The CEO's $7.5M sale at $100 is the largest insider sale in the trailing 30-day period ($11.9M total). While the company just reported transformative earnings, insider selling at these levels suggests limited near-term upside conviction. Monitor for additional insider sales or any lockup expiration disclosures. The stock's 89% analyst bullish rating may face headwinds if insiders continue to reduce positions.
PTGX drugs
PTGX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 8 $99.36entry
- T+1 · 6mo ago +4.17%α +3.93% · $103.50
- T+5 · 6mo ago +6.23%α +4.77% · $105.55
- T+20 · 5mo ago −1.99%α −2.02% · $97.38
- T+60 · 3mo ago +36.68%α +31.85% · $135.81
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CEO Dinesh Patel and Director Bryan Giraudo sold a combined $11.7M in open-market shares within a week of PTGX reporting a massive Q1 2026 earnings beat (revenue $56.4M vs. $16.3M consensus, EPS $0.05 vs. -$0.65 consensus). The sales follow the FDA approval of ICOTYDE and a $200M rusfertide opt-out payment, but the CEO's $7.5M sale at ~$100/share, near all-time highs, raises questions about insider conviction at current valuation. At $11.7M total open-market sales, this represents ~0.17% of PTGX's $6.7B market cap, which is modest but notable given the CEO's participation and the post-earnings timing.
Key Financial Metrics
Key Facts
- CEO Dinesh Patel sold 75,000 shares at $100.12 for $7.51M on May 12, 2026
- Director Bryan Giraudo sold 36,000 shares at $100.14 for $3.61M on May 7, 2026
- Total open-market sales: $11.71M (0.17% of $6.7B market cap)
- Sales occurred 2-7 days after Q1 2026 earnings beat (revenue $56.4M vs. $16.3M consensus)
- CEO also exercised 150,000 options at $0 and $21.58 strike prices (non-cash events)
- Stock is trading near all-time highs following ICOTYDE FDA approval and $200M milestone payment
Financial Impact
Insider sales of $11.71M represent 0.17% of market cap, modest but notable given CEO participation
Risk Factors
- CEO selling near all-time highs may signal peak valuation sentiment
- Further insider sales could pressure stock price
- Post-earnings momentum may fade without additional catalysts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PTGX-1778628514248 |
Track record
11 reports on PTGX
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +31.42% at T+60 after the May 5, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Bullish 7/10 Entry $132.04 Now $124.83 −5.46% settles Feb 4
- Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $143.37 Now $124.83 −12.93% settles Feb 2
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $142.14 Now $124.83 −12.18% settles Jan 26
- Aug 10, 202614w ago 144 Bearish 5/10 Entry $148.29 to $143.37 Now $124.83 +15.82% ▲ +3.32% +2.83% vs SPY
- Jun 18, 202621w ago 8-K Neutral 3/10 Entry $115.03 to $143.40 Now $124.83 +8.52% ▲ +24.66% +22.92% vs SPY
- Jun 12, 202622w ago Institutional Cluster Mixed 5/10 Entry $109.78 to $145.94 Now $124.83 +13.71% ▲ +32.94% +29.67% vs SPY
- May 12, 202626w ago 144 Bearish 5/10 Entry $103.88 to $145.87 Now $124.83 −20.17% ▼ −40.42% −35.98% vs SPY
- May 8, 202627w ago Insider Cluster Neutral 4/10 Entry $99.36 to $135.81 Now $124.83 +25.63% ▲ +36.68% +31.85% vs SPY
- May 8, 202627w ago Insider Cluster Neutral 5/10 Viewing Entry $99.36 to $135.81 Now $124.83 +25.63% ▲ +36.68% +31.85% vs SPY
- May 5, 202627w ago 8-K Bullish 7/10 Entry $103.97 to $136.64 Now $124.83 +20.06% ▲ +31.42% +29.36% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers